Viking Therapeutics ( ($VKTX) ) has risen by 7.76%. Read on to learn why. Viking Therapeutics has seen a notable 7.76% ...

Viking Therapeutics reported a solid financial standing with $808 million in cash, cash equivalents, and short-term investments. This strong cash position provides a substantial financial runway to ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $30.0 and $60.0 for Viking Therapeutics, spanning the last three ...

Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

In addition to Stifel Nicolaus, Viking Therapeutics also received a Buy from William Blair’s Andy Hsieh in a report issued today. However, yesterday, Citi maintained a Hold rating on Viking ...

Viking Therapeutics, Inc. ( NASDAQ: VKTX) Q2 2025 Earnings Conference Call July 23, 2025 4:30 PM ET Brian Lian - President, CEO & Director Gregory Zante - Chief Financial Officer ...

Viking Therapeutics shares fall in Wednesday's after-hours session after the company reported financial results for the ...

Investing.com -- Viking Therapeutics, Inc. (NASDAQ: VKTX) reported a wider-than-expected second quarter loss on Wednesday, sending shares down 4.2% as investors reacted to the earnings miss despite ...

Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Every investor in Viking Therapeutics, Inc. (NASDAQ:VKTX) should be aware of the most powerful shareholder groups. We can see that institutions own the lion's share in the company with 70% ownership.

Justin Jefferson led the Minnesota Vikings to a 14-3 record last season, the second-best in franchise history. Jefferson and ...

Key Points CRISPR Therapeutics is still in its early growth stage.Summit Therapeutics has plenty of upside potential ...